格隆汇1月29日丨珠江钢琴(002678.SZ)发布2025年度业绩预告，预计2025年度净亏损39,500万元–35,000 万元，上年同期亏损23,562.25万元；扣非净亏损39,800万元–35,500万元，上年同期亏损23,542.48万元。 受国内外经济形势波动、消费市场结构调整等多重外部因素交织影响，钢琴主业市场需求持续大幅萎 缩；叠加公司产能收缩推高单位成本、人员优化及资产减值计提等内部因素，公司利润总额较上年同期 下滑。 面对市场持续收缩与行业深度调整，公司主动推进产能结构优化与工艺布局调整，系统化盘活闲置资 产，统筹多地厂房资源开展整合、出租及再利用工作；同时，公司聚焦主业升级与新赛道拓展，积极布 局文旅、演艺灯光等新业务，加速重点项目落地，持续优化产业布局，推动公司实现转型升级与可持续 发展。 ...

Core Insights - Longshen Rongfa has received the Medical Device Registration Certificate for its blood dialysis powder, marking its entry into the medical device sector and filling a market gap in the northwest region of China [1][2] Company Developments - The product's registration certificate is valid from November 5, 2025, to November 4, 2030, indicating a long-term commitment to the medical device market [1] - Longshen Rongfa is the first company in the northwest provinces of Gansu, Qinghai, Ningxia, and Xinjiang to successfully obtain this registration, enhancing its competitive position [1] - The blood dialysis powder is designed for both acute and chronic renal failure treatments and is compatible with various brands of dialysis machines, addressing a wide range of patient needs [1] Market Potential - According to the Chinese Medical Association, the total number of dialysis patients in mainland China is projected to reach 1.183 million in 2024, with 1.027 million undergoing blood dialysis, indicating a growing market for dialysis-related products [2] - The company is also advancing the construction of production lines and obtaining production licenses for related products, including blood dialysis concentrates, which will further expand its product offerings and revenue streams [2] - The anticipated launch of these products is expected to create new profit growth points and support the company's long-term development strategy [2]